CD274 and breast carcinoma: In breast cancer patients, RT failed to improve ORR to ICBs at both local and distant sites when administered in combination with PD-L1/PD-1 blockades [121,141], and only 18% of TNBC patients who were enrolled to receive RT plus pembrolizumab achieved durable complete responses.